ClinicalTrials.gg
CompletedNCT01506752Updated Jun 27, 2012

A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males

A Phase 1 interventional study of Donepezil Hydrochloride and Donepezil Hydrochloride in Healthy Adult, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-27.

Sponsored by Eisai Co., Ltd. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 44 Years
Sex
Male
01

Study summary

The purpose of this study is to investigate the bioequivalence of improved and current orally disintegrating E2020 10 mg tablets as a single dose in Japanese healthy adult males for each of two administration methods (with/without water).

02

Conditions studied

  • Healthy Adult

Keywords

  • Bioequivalence
  • Healthy Subjects
  • Donepezil
03

In context

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 44 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Those who meet all below criteria are eligible to enroll in this study;

  1. Those who provide consent by their own will.
  2. Male subjects aged between ≥ 20 years and \< 45 years old at the time of obtaining and non-smoker (subjects who have not been smoking for at least 4 weeks prior to study treatment)
  3. at screening is 18.5 kg/m2 or above and less than 25.0 kg/m2
  4. Those who are willing to and can comply with the conditions described in the study protocol.

Exclusion criteria

Exclusion Criteria

Those who meet any of the below criteria will be excluded from the study.

  1. Any significant medical illness that required intervention within 8 weeks before treatment, or any medical history of infectious diseases within 4 weeks before treatment.
  2. Those who had any psychiatric, GI tract, hepatic, renal, respiratory, endocrine, hematological, neurological, cardiovascular diseases or congenital metabolic disorders within 4 weeks before study drug administration that may have an impact on the evaluation of the drug.
  3. Subjects who have any medical history of GI, hepatic, or renal surgery (e.g. excision of liver, kidney or GI tract) that may have an impact on pharmacokinetics of the drug.
  4. Subjects who have any history of medically significant allergy to medications or foods, and those who currently have any symptoms of seasonal
  5. Subjects whose weight changes were more than 10% from the screening phase to study drug administration.
  6. Those with clinical abnormal symptoms, medical history of organ dysfunction, subjective symptoms, objective findings, vital signs, and abnormal or clinical laboratory test values, which need medical intervention.
  7. Corrected change in wave (QTc) interval of > 450 msec with 12-lead EKG at screening or study drug administration.
  8. Subjects who are positive for surface antigen (HBs antigen), (HCV) antibody, or serologic test for syphilis (STS).
  9. Subjects who are suspected with or who has a history of drug or alcohol abuse, or positive urine screen for drugs of abuse or exhalation alcohol test at screening or baseline.
  10. Subjects who consumed caffeine-containing food or beverages within 72 hours before study drug administration.
  11. Exposure to any supplements or herbs (including Chinese medicine), or beverages (e.g. alcohol or grapefruit-containing beverages, within 2 weeks of study drug administration.
  12. Exposure to St. John's wort containing medications within 4 weeks of study drug administration.
  13. Use of any prescription drugs within 4 week before study drug administration.
  14. Use of any OTC medications within 2 week before study drug administration.
  15. Subjects who enrolled in another clinical trial and exposed to any drug within 16 weeks of study enrollment.
  16. Subjects who received blood infusion within 12 weeks, those who had blood drawn 400 mL or more within 12 weeks, 400 mL, or 200 mL or more within 4 weeks, or sampling of a component of the blood within 2 week of study drug administration.
  17. Subjects who performed extreme exercises or exhausting labors (more than 1 hr/day or 5 day/week) within 2 weeks before hospitalization.
  18. Any subject who, or whose partner, does not want to take highly reliable measures until the end of the post-treatment examination.
  19. Subjects who are inappropriate to participate in the study, as judged by the investigator or subinvestigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    E2020 improved 10 mg without water

    Drug: Donepezil Hydrochloride

  • Active comparator
    E2020 current 10 mg without water

    Drug: Donepezil Hydrochloride

  • Active comparator
    E2020 improved 10 mg with water

    Drug: Donepezil Hydrochloride

  • Active comparator
    E2020 current 10 mg with water

    Drug: Donepezil Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. PK Parameter Cmax, calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated.

    Time frame: Up to 168 hrs after administration

  2. PK Parameter AUC(0-168), calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated.

    Time frame: Up to 168 hrs after administration

07

Study locations

1 site
  • Sumida-ku, Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2012
First posted
Jan 10, 2012
Start
Jul 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Jun 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01506752
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jan 10, 2012
Start date
Jul 2011
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Jun 27, 2012

Study contacts

Hiroki Shimizu
study director · Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion